Diefenbach Lab

Research focus

NIH R01 · 2024

A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunity

ABSTRACT/SUMMARY Diffuse large B-cell lymphoma (DLBCL), the most common lymphoma, is a significant clinical problem, with only 60% of patients cured. Mechanisms for how DLBCL, an immune cancer, evades host defenses are poorly understood. Growing evidence suggests that the human gut microbiota (GMB) plays important roles in regulating innate and adaptive immunity, and is associated with therapeutic outcome in multiple solid tumor types. Based on this connection, we hypothesize that the GMB influences lymphoma behavior by altering the anti-tumor immune response. Our preliminary data provide compelling evidence that DLBCL patients: a) have distinct GMB compositions in which many commensal…

From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.